We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Faulty Immune-Boosting Cells Initiate Autoimmunity

By Biotechdaily staff writers
Posted on 13 Mar 2006
The failure of programming that triggers the death of dendritic cells, those that activate the immune system, can initiate autoimmune disease, according to researchers in a recent report that appears in the February 24, 2006, issue of the journal Science. More...

The problem begins with a process called programmed cell death, or apoptosis, according to Dr. Jin Wang, assistant professor of immunology at Baylor College of Medicine (Houston, TX, USA). Mice engineered to have a defect in apoptosis of their dendritic cells went on to develop autoimmune disease, Dr. Wang said. "This suggests that defective apoptosis of dendritic cells can be a critical component of autoimmune diseases.”

Autoimmune diseases, such as lupus and juvenile diabetes, occur when the immune system begins attacking the body's own tissues instead of foreign organisms. "We knew that autoimmunity in general can be caused when dendritic cells are unchecked, either by programmed cell death or overactivation,” said Dr. Wang. "Dendritic cells are the initiators of immunity.” They do this by showing or presenting foreign antigens from invading bacteria or viruses to the immune system, which then triggers lymphocytes to attack.

Before this, many scientists believed autoimmunity occurred through apoptosis because of accumulating lymphocytes or white blood cells--major components of the immune system. "If they didn't die, we thought they would start to accumulate and do damage to the body's own tissues,” Dr. Wang stated. However, at least eight studies that suppressed programmed cell death in lymphocytes did not induce autoimmune disease in animals.

In the future, Dr. Wang and his colleagues plan to fill in the gaps between what occurs when apoptosis is hindered in the dendritic cells and the occurrence of autoimmune disease.



Related Links:
Baylor College of Medicine

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Prefilled Tubes
Prefilled 5.0ml Tubes
New
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.